We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




License Deal for GPCR Drug Discovery

By Biotechdaily staff writers
Posted on 11 Jul 2002
A nonexclusive license to proprietary technology for drug discovery has been granted by the developer, Norak Biosciences (Research Triangle Park, NC, USA), to AstraZeneca (London, UK).

AstraZeneca will use the technology, Transfluor, for an internal G protein-coupled receptor (GPCR) drug discovery project. More...
AstraZeneca is to provide feedback to Norak on the performance and results of Transfluor use in high throughput screening against a large compound library. Norak will provide ongoing technology support and know-how related to GPCR targets. GPCRs are cell surface targets to which drugs bind to cause changes in intracellular function and are the richest receptor targets for drug discovery.

"The evaluation of the Transfluor technology to date has demonstrated the potential for this assay to contribute to AstraZeneca's drug discovery program,” said Elaine Sullivan, Ph.D., director of The Advanced Science and Technology Laboratory, AstraZeneca.

The patented Transfluor technology is designed to be the most accurate method for discovering ligands for GPCR targets, whether known or orphan. Norak is offering limited access to its Transfluor technology to the pharmaceutical industry via licensing and collaborations and is also conducting internal research to discover drugs for its own pipeline.




Related Links:
Norak

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Immunofluorescence Analyzer
IFA System
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.